Precision medicine takes a significant leap forward with engineered cytokines that remain dormant until activated at specific tissue sites. This breakthrough addresses a fundamental challenge in immunotherapy: how to harness the power of immune signaling molecules without triggering widespread, potentially dangerous responses throughout the body. The innovation centers on Sterically Masked Activated Cytokines (SMACks), where therapeutic cytokines are deliberately blocked by molecular masks that only release the active protein when specific conditions are met at target locations. The platform demonstrates remarkable versatility, allowing researchers to customize both the cytokine payload and the activation mechanism based on the intended therapeutic application. Early testing shows these masked cytokines can deliver potent immune responses precisely where needed while remaining essentially inert in healthy tissues. This represents a fundamental shift from systemic cytokine therapy, which often causes severe side effects due to widespread receptor activation. The modular design means the same platform can potentially be adapted for treating autoimmune diseases, cancers, or chronic inflammatory conditions by simply swapping different cytokines and targeting mechanisms. However, the technology remains in early development stages, with questions about long-term safety, manufacturing scalability, and real-world efficacy still to be answered. The approach builds on decades of protein engineering advances but represents a novel solution to the selectivity problem that has limited cytokine therapeutics. If successful in clinical trials, SMACks could transform treatments for immune-related disorders by providing the therapeutic benefits of cytokines while minimizing their notorious side effect profiles.